NCT07611812Completed
Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 14 May 2026
- Start date
- 4 Feb 2021
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Diseases
- Multiple myeloma
- NCT number
- NCT07611812
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 4 Feb 2021 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- the patient's refusal to participate
Who the study is looking for
- Patients with multiple myeloma (MM) at first relapse treated starting in January 2017 with RD-based triplets in accordance with current clinical practice
- Age ≥18 years
- Written informed consent signed by the patient
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.